Name | T-1101 tosylate |
Description | T-1101 tosylate (TAI-95 tosylate) is a Hec1/Nek2 inhibitor with antitumor activity. |
Animal Research | SCID mice bearing human Huh-7, BT-474, MCF-7, and MDA-MB-231 xenografts. Dosage:25 mg/kg, 50 mg/kg. Oral administration; twice per day; 28 days |
In vitro | T-1101 has good oral absorption, along with potent in?vitro antiproliferative activity (IC50: 14.8-21.5?nM). |
In vivo | T-1101 tosylate can achieve high concentrations in Huh-7 and MDA-MB-231 tumor tissues, and showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7). |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 11 mg/mL (16.52 mM)
|
Keywords | TAI95 | T1101 Tosylate | T1101 tosylate | T-1101 Tosylate | TAI95 Tosylate | TAI-95 | T 1101 Tosylate | T1101 | Apoptosis | Inhibitor | inhibit | T 1101 | T-1101 | TAI-95 Tosylate | PPI | TAI 95 | Hec1/Nek2 | TAI 95 Tosylate | T 1101 tosylate |
Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Microtubule-Targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |